Codice QR

Synergistic anticancer effects of camptothecin and sotorasib in KRAS-mutated pancreatic ductal adenocarcinoma

BackgroundSotorasib (AMG510) is a first-in-class irreversible, covalent, and selective KRAS G12C inhibitor. However, in patients, acquired clinical resistance was observed within 1 year of its FDA approval. Researchers are exploring combination and repurposing strategies to help overcome this resist...

Descrizione completa

Salvato in:
Autori principali: Prasanna Srinivasan Ramalingam, Gayathri Chellasamy, Md Sadique Hussain, Gothandam Kodiveri Muthukaliannan, Tajamul Hussain, Salman Alrokayan, Kyusik Yun, Janaki Ramaiah Mekala, Sivakumar Arumugam
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2025-07-01
Serie:Frontiers in Pharmacology
Soggetti:
alkaloid
camptothecin
sotorasib
KRAS mutation
PDAC
synergistic effect
Accesso online:https://www.frontiersin.org/articles/10.3389/fphar.2025.1635449/full
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi